Modest guidance from Novo Nordisk for 'tricky' 2014
This article was originally published in Scrip
Executive Summary
Novo Nordisk has reported a sales growth of 12% in local currencies during 2013 driven by growth in sales of Victoza, NovoRapid and Levemir. However, sales growth for 2014 has been guided at 8-11% in local currencies, lower than expected, but Novo did raise its guidance three times during 2013.